Prima BioMed Ltd. is developing an autologous (the body's own) immune therapy for the treatment of epithelial ovarian carcinoma (ovarian cancer). Before the socalled CVac therapy can obtain approval and be used for treating patients, its safety and efficacy must be proved in a clinical study. According to Prima BioMed Ltd., first results of previous studies are highly promising.
Together with the Fraunhofer IZI the Australian company intends to conduct the clinical trial and to obtain approval for the novel therapy. In this context the Fraunhofer IZI is particularly responsible for the manufacture of investigational medicinal products and the conduct of quality controls for the European arm of the study. This joint project is funded with 4.1 million Euros by the Development Bank of Saxony (Sächsische Aufbaubank). On August 8, 2011, Saxonian State Minister Prof. Dr. Dr. Sabine von Schorlemer personally presented the funding grant, thus emphasizing the significance of such innovative projects for the Free State of Saxony.
In order to introduce the therapy to the European market as soon as possible, the Australian company has founded a German subsidiary based in Leipzig. Matthew Lehman, managing director of the Prima BioMed GmbH, is enthusiastic about the location of Leipzig. "The comprehensive support for Prima BioMed and our CVac program by the Free State of Saxony is overwhelming. With the Fraunhofer IZI, this region offers an advanced research infrastructure combined with excellent funding options through the Development Bank of Saxony, advantageous biologistics provided by the airport Leipzig-Halle and an outstanding research and development landscape. We are glad to be able to control our activities in Europe from Leipzig and are looking forward to a longterm commitment in this region".
Dr. Gerno Schmiedeknecht, Head of the Department of Cell Engineering at the Fraunhofer IZI, is glad about the cooperation. "We are proud to support Prima BioMed in the development of the CVacTM technology. It is our common goal to provide this promising therapy as soon as possible to as many patients as possible".
The autologous immune therapy CVacTM is based on the modification of the body's own immune cells. Tumor cells are capable of evading the immune defense in various ways. The CVacTM method modifies the patient's specialized immune cells so as to make them recognize the tumor cells and activate diverse defense mechanisms of the immune system. These so-called dendritic cells are targeted to recognize a specific protein (biomarker) that is present exclusively on the tumor cells. The immune system is thus capable of specifically attacking the tumor cells without affecting healthy cells. This form of treatment is therefore much gentler for the patient than irradiation and chemotherapies and also holds the promise of lower relapse rates.
One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center
The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology